安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- The PRISMA 2020 statement: an updated guideline for reporting . . .
DOI: 10 1136 bmj n71 Abstract The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found
- The PRISMA 2020 statement: an updated guideline for reporting . . . - The BMJ
BMJ 2021; 372 doi: https: doi org 10 1136 bmj n71 (Published 29 March 2021) Cite this as: BMJ 2021;372:n71 Linked RMR PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
- Abstracts — PRISMA statement
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021;372:n71 doi: 10 1136 bmj n71 Note: This abstract checklist is an update of the 2013 PRISMA for Abstracts statement, reflecting new and modified content in PRISMA 2020
- The PRISMA 2020 statement: An upd. . . preview related info - Mendeley
The BMJ The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found
- Characteristics of intervention studies on . . . - BMJ Paediatrics Open
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram Notes: PRISMA flow diagram according to Page MJ, McKenzie JE, Bossuyt PM, et al The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ 2021;372:n71 doi: 10 1136 bmj n71 RCT, randomised controlled trial
- Isometric exercise training and resting arterial blood pressure . . .
BMJ 2021; 372: n71 doi:10 1136 bmj n71 Footnotes X @EdwardsJ361 Contributors JE completed the data interpretation and drafting of the manuscript and took responsibility for the integrity of the information Funding The authors have not declared a specific grant for this research from any funding agency in the public,
- Prevalence of polypharmacy in pregnancy: a systematic review - BMJ Open
BMJ 2021; 372: 71 doi:10 1136 bmj n71 OpenUrl CrossRef PubMed Supplementary materials Supplementary Data This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content Data supplement 1; Data supplement 2
- Outcome measures for randomised clinical trials and multicentre . . .
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The increasing use of composite outcome measures, expansion in the number of secondary outcome measures employed per study and variation in the primary outcome measures reported and their definitions contribute to biases and potentially make interpretation, cross-study comparisons and marketing applications problematic
|
|
|